LINK to register
From the 340B Coalition:
2018 remains fraught with potential for major changes to the 340B drug discount program. This is just a taste of the 340B issues that will be on the menu when an anticipated record-breaking +1,600 340B program stakeholders gather in Washington in early July for the 340B Coalition Summer Conference:
The legislative front – Bills have been introduced in the U.S. House and Senate that would alter the 340B program, including scaling back hospital participation and reducing the number of sites eligible for discounts. The House Energy & Commerce Committee issued a report early this year calling for big changes to 340B but it still hasn’t tipped its hand about its next move. The Senate Health, Education, Labor, and Pensions Committee held a March 15 hearing on the program and Chairman Lamar Alexander (R-Tenn.) says he plans to hold at least one more. At the same time, bipartisan legislation to nullify the $1.6 billion Medicare Part B drug reimbursement cut to 340B hospitals is edging closer to gaining its 200th sponsor. On top of it all, more than half of Americans say passing legislation to bring drug prices down should be a “top priority” for President Trump and Congress.
The regulatory front – The Trump administration is considering delaying for the fifth time publication of regulations establishing civil monetary penalties for drugmakers that overcharge 340B providers. They have also pushed back plans to post a secure website to give 340B providers access to 340B ceiling price information. By the time of the summer conference, a federal appeals court is expected to have handed down a decision in the lawsuit challenging the legality of the regulation that chopped 340B hospitals’ Medicare Part B drug reimbursement this year by almost 30 percent.
For providers, pharmacies, service providers, drug manufacturers, and government agencies alike, attending the conference is the best way to stay on top of 340B.